Abstract
Peroxisome Proliferator-Activated Receptor-γ (PPARγ) is an extensively studied ligand-activated nuclear hormone receptor that functions as transcription factor and plays an important role in diverse biological processes, such as lipid metabolism and insulin sensitization. Recent studies have demonstrated that PPARγ is over-expressed in many tumor types, including breast cancer, suggesting a possible role in tumor development and/or progression and a putative prognostic value. Moreover, naturally-occurring and synthetic PPARγ agonists promote growth inhibition, apoptosis and differentiation of tumor cells. The present review summarizes the available information on PPARγ expression in breast tumors and the use of PPARγ ligands as anti-cancer agents for breast cancer treatment, both in vitro and in vivo. Considering the data so far, specific PPARγ agonists seem to exert beneficial effects against breast cancer and may therefore represent potential therapeutic agents.
Keywords: 15-deoxy-Δ12, 14-prostaglandin J2 (15d-PGJ2), Anti-cancer agents, Apoptosis, Breast cancer, Cell cycle arrest, Differentiation, Estrogen Receptors (ERs), Fatty acids, Growth inhibition, Ligands, Methylene-substituted diindolylmetyhanes (CDIMs), Oncogenesis, Peroxisome Proliferator-Activated Receptor-γ (PPARγ), Prognostic value, Retinoid-X-Receptor (RXR), Statins, Thiazolidinediones (TZDs)
Anti-Cancer Agents in Medicinal Chemistry
Title:The Role of Peroxisome Proliferator-Activated Receptor-γ in Breast Cancer
Volume: 12 Issue: 9
Author(s): Ioly Kotta-Loizou, Constantinos Giaginis and Stamatios Theocharis
Affiliation:
Keywords: 15-deoxy-Δ12, 14-prostaglandin J2 (15d-PGJ2), Anti-cancer agents, Apoptosis, Breast cancer, Cell cycle arrest, Differentiation, Estrogen Receptors (ERs), Fatty acids, Growth inhibition, Ligands, Methylene-substituted diindolylmetyhanes (CDIMs), Oncogenesis, Peroxisome Proliferator-Activated Receptor-γ (PPARγ), Prognostic value, Retinoid-X-Receptor (RXR), Statins, Thiazolidinediones (TZDs)
Abstract: Peroxisome Proliferator-Activated Receptor-γ (PPARγ) is an extensively studied ligand-activated nuclear hormone receptor that functions as transcription factor and plays an important role in diverse biological processes, such as lipid metabolism and insulin sensitization. Recent studies have demonstrated that PPARγ is over-expressed in many tumor types, including breast cancer, suggesting a possible role in tumor development and/or progression and a putative prognostic value. Moreover, naturally-occurring and synthetic PPARγ agonists promote growth inhibition, apoptosis and differentiation of tumor cells. The present review summarizes the available information on PPARγ expression in breast tumors and the use of PPARγ ligands as anti-cancer agents for breast cancer treatment, both in vitro and in vivo. Considering the data so far, specific PPARγ agonists seem to exert beneficial effects against breast cancer and may therefore represent potential therapeutic agents.
Export Options
About this article
Cite this article as:
Kotta-Loizou Ioly, Giaginis Constantinos and Theocharis Stamatios, The Role of Peroxisome Proliferator-Activated Receptor-γ in Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (9) . https://dx.doi.org/10.2174/187152012803529664
DOI https://dx.doi.org/10.2174/187152012803529664 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Oxidative Stress and Beyond: Multiple Functions of the Protein Glutathionylation
Protein & Peptide Letters Recent Patents on Morphometric Analysis of Eukaryotic Cells
Recent Patents on Medical Imaging Anticancer Activity and In Silico ADMET Properties of 2,4,5-Trisubstitutedthiazole Derivatives
Current Drug Metabolism Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Protease Inhibitors in the Clinic
Medicinal Chemistry Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Current Medicinal Chemistry Hedgehog Signaling and Urological Cancers
Current Drug Targets Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas
Current Cancer Drug Targets Exosomal MicroRNAs in Tumoral U87 MG Versus Normal Astrocyte Cells
MicroRNA Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Anti-Breast Cancer Activities of Ketoprofen-RGD Conjugate by Targeting Breast Cancer Stem-Like Cells and Parental Cells
Anti-Cancer Agents in Medicinal Chemistry Fused and Substituted Pyrimidine Derivatives as Profound Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Neurodevelopment in Schizophrenia: The Role of the Wnt Pathways
Current Neuropharmacology Electron Emission of Phytohormone Genistein. Pathway for Communication
Current Bioactive Compounds Hypertension and Angiogenesis
Current Pharmaceutical Design A Comparative Study of the Cytotoxic and Pro-apoptotic Properties of Nepeta binaloudensis
Letters in Drug Design & Discovery 4-Anilino-3-quinolinecarbonitriles: An Emerging Class of Kinase Inhibitors - An Update
Medicinal Chemistry Reviews - Online (Discontinued) Inhibition of Human Aromatase by Myosmine
Drug Metabolism Letters